Clinical Trials Logo

Familial Pancreatic Cancer clinical trials

View clinical trials related to Familial Pancreatic Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04247503 Active, not recruiting - Clinical trials for Familial Pancreatic Cancer

Cohort Study of Pancreatic Cancer Risk

Start date: December 11, 2019
Phase:
Study type: Observational

This study is designed to develop a cohort of individuals without pancreatic cancer, but who are at increased risk of developing it due to family history or genetic predisposition. These high-risk individuals will be asked to provide baseline and annual (serial) follow-up blood samples for the duration of the study funding. Mayo Clinic is part of a national Pancreatic Cancer Detection Consortium (PCDC)[1] which aims to establish a high-risk cohort with the goal of validating blood biomarkers (discovered/developed outside of this protocol) using the samples collected serially (annually) that predict or detect pancreatic cancer prior to clinical diagnosis.

NCT ID: NCT02206360 Active, not recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Early Detection Program

PCEDP
Start date: April 2014
Phase:
Study type: Observational [Patient Registry]

Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.